In case you missed it: April 5 to April 9
It was a very busy week for the Contemporary OB/GYN® team.
This week’s top articles included:
Hormone therapy for postmenopausal women with nocturia
A prospective observational study found that hormone therapy resulted in a significant reduction in nocturia prevalence and bother in postmenopausal women with two nocturnal voids.
Oral contraceptive and ovarian function
A prospective study to assess the effects of an oral contraceptive containing estetrol and drospirenone on ovarian function found treatment achieved complete ovulation inhibition.
Current Management of Uterine Fibroids
Two experts discuss the goals of treatment and the expanding therapeutic landscape. This article was sponsored by Myovant Sciences.
Reduced Testing, Higher Positivity Rates for Prescription and Illegal Drugs During the COVID-19 Pandemic in 2020
Lower levels of testing and higher positivity rates, higher rates of dangerous drug combination use, and increases in fatal and non-fatal overdoses during the coronavirus disease 2019 (COVID-19) pandemic reveal a need for more resources to address the opioid epidemic in the United States.
Evaluation & Management of COVID-19 in Pregnancy
Treating COVID-19 in pregnant patients brings extra challenges, risks.
SKYLIGHT trials confirm safety and efficacy of fezolinetant against sleep disturbances
September 13th 2024At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.
Read More
Study shows hormone therapy offers lasting benefits for women over 65
September 12th 2024A new study presented at the 2024 Annual Meeting of The Menopause Society shows hormone therapy remains beneficial for women over 65, helping manage menopause symptoms like hot flashes and improving quality of life.
Read More
